Body Pharm GHK-Cu 50 Pen

The Body Pharm GHK-Cu 50 Pen is a 50 mg pre-mixed copper tripeptide-1 (GHK-Cu) research device delivering 30 ready-to-use doses at approximately 3 mg each — no reconstitution, no bacteriostatic water, no pipetting variance. It is available through JCSG.org for Australian research accounts, with the current price shown in the buy box.

Key Takeaways

• 50 mg GHK-Cu per pen in a pre-mixed stable solution — 30 doses at ~3 mg each, straight from the pen.
• No reconstitution required — eliminates bacteriostatic water calculation and pipetting error common with lyophilised vials.
• GHK-Cu research covers in vitro collagen synthesis, fibroblast function, wound-healing signalling, and hair-follicle models; pre-clinical evidence only as of 2026.
• Request a batch-specific COA from JCSG.org when ordering to confirm purity and concentration for your study records.

What Is the Body Pharm GHK-Cu 50 Pen?

The Body Pharm GHK-Cu 50 Pen contains 50 mg of glycyl-L-histidyl-L-lysine copper complex (copper tripeptide-1) in a multi-dose injector device, providing approximately 30 doses at ~3 mg per dose. GHK-Cu is a naturally occurring copper-binding tripeptide first isolated from human plasma. It has been studied extensively in vitro for collagen synthesis, skin regeneration, fibroblast function, and extracellular matrix signalling [6].

The pen format removes the reconstitution step entirely. The peptide arrives in solution at a fixed concentration, dosed via a click-graduated mechanism — eliminating bacteriostatic water calculation, syringe-draw variance, and the reconstitution contamination risk that sealed vials introduce. For labs running distributed or multi-operator protocols, that consistency removes a key variable; dose-dial accuracy becomes the main precision constraint.

Product Specifications

Parameter	Value
Active peptide	GHK-Cu (copper tripeptide-1)
Total peptide per pen	50 mg
Doses per pen	30 (vendor-stated)
Dose size	~3 mg (vendor-stated)
Format	Pre-mixed stable solution
Positioning	Research / laboratory use only

Request a current batch COA from JCSG.org at time of order to verify concentration and purity for your study records.

Researchers comparing pen formats across the Body Pharm range may also be interested in the Body Pharm BPC-157 & TB500 32 Pen and the Body Pharm CJC-1295 & Ipamorelin 20 Pen.

GHK-Cu Research Background (2026 Evidence Summary)

GHK-Cu has been investigated primarily in vitro and in animal models for collagen synthesis, angiogenesis, wound healing, hair follicle stimulation, and muscle fibre regeneration. As of 2026, no large-scale human randomised controlled trial confirming therapeutic efficacy is indexed [8]. Procurement officers should treat the literature as mechanistic and pre-clinical, not as clinical proof of outcome.

The most directly relevant recent work covers two in vitro lines of inquiry. First, lung fibroblasts from chronic obstructive pulmonary disease (COPD) donors, where GHK-Cu was reported to restore aspects of fibroblast function. Second, skin-derived cell lines, where collagen and elastin markers increased relative to controls [8]. These findings show GHK-Cu can modulate fibroblast behaviour in human-derived cells, even though the effect has not been replicated in living human subjects. Older mechanistic studies on gene modulation and wound-healing pathways pre-date 2023 and should be treated as background context [9].

Experimental Models in the 2023–2026 Literature

Model class	Reported endpoint	Evidence tier (2026)
Skin fibroblast culture	Collagen / elastin synthesis markers	In vitro
COPD lung fibroblast culture	Fibroblast functional restoration	In vitro
Wound-healing signalling assays	ECM gene expression modulation	In vitro, pre-2023 baseline
Hair follicle dermal papilla assays	Follicle stimulation markers	In vitro, pre-clinical

The 2026 UNSW Newsroom analysis of injectable anti-ageing peptides explicitly groups GHK-Cu among compounds where consumer use has outpaced human trial evidence [1]. In vitro findings do not translate automatically to human outcomes. Researchers cross-referencing tissue-repair peptide protocols often pair GHK-Cu reading with literature on the Body Pharm BPC-157 & TB500 32 Pen, since BPC-157 and TB-500 share the wound-healing endpoint space in pre-clinical models.

Pre-Mixed Pen vs Lyophilised Powder: Research Rationale

A pre-mixed peptide pen removes the reconstitution step entirely. The peptide arrives in solution at a fixed concentration, dosed via click-graduated mechanism, which removes the bacteriostatic water calculation, syringe-draw variance, and reconstitution contamination risk that vials introduce.

Practical handling advantages:

• Dose-to-dose concentration is fixed by the manufacturer, not the operator — a common source of inter-experiment variance disappears.
• Click-counted dosing reduces protocol error in multi-operator research settings where syringe technique varies between staff.
• 30 ready administrations per pen without ancillary diluent stock — simplifying consumables costing per study arm.

The trade-off is lower flexibility to vary dose volumes mid-study, which lyophilised powder reconstituted at the bench preserves.

Post-activation shelf life is the other key consideration. A pen, once in solution and broached, is constrained by the manufacturer's stated in-use period. The BodyPharm GHK-Cu 50 mg pen is described as a "stable solution format"; confirm the specific in-use duration and cold-chain shipping requirements with JCSG.org at time of order.

Researchers comparing format choices across the Body Pharm range may also reference the Body Pharm BPC-157 & TB500 32 Pen and Body Pharm CJC-1295 & Ipamorelin 20 Pen for consistency of dosing mechanism across a multi-peptide protocol.

Body Pharm GHK-Cu 50 Pen — Full Specifications

The table below consolidates the vendor-stated specifications for the Body Pharm GHK-Cu 50 Pen.

Parameter	Body Pharm GHK-Cu 50 Pen
Total GHK-Cu	50 mg
Vendor-stated dose count	30 doses
Vendor-stated dose size	~3 mg
Current price	See buy box
Shelf stability	"Stable solution format"; confirm in-use duration on order
Cold-chain	Confirm with JCSG.org at time of order
Purchase (Australia)	Available via JCSG.org

All specifications are vendor-stated and subject to change. Request a batch COA on invoice.

Understanding the Specifications

Concentration (50 mg per pen) determines how many experimental runs a single unit supports before reorder. A factory-metered 30-dose pen removes pipetting drift between subjects within the same protocol arm.

Shelf stability and cold-chain shipping govern procurement lead time. Australian labs ordering need a documented in-use window that covers transit plus study duration. Confirm the specific shipping pathway and in-use period with JCSG.org when placing your order.

Researchers benchmarking pen-format consistency within Body Pharm's range can cross-check the Body Pharm BPC-157 & TB500 32 Pen and Body Pharm CJC-1295 & Ipamorelin 20 Pen.

Australia Availability and Regulatory Context (2026)

The Body Pharm GHK-Cu 50 Pen is available to Australian researchers via JCSG.org.

GHK-Cu is positioned exclusively as a research or laboratory use material and is not approved for human therapeutic use in Australia. The 2026 UNSW Newsroom explainer on injectable peptides groups GHK-Cu among compounds where research interest has outpaced clinical trial evidence [1]. GHK-Cu is not individually named in the consolidated Australian Poisons Standard at the time of writing, but unscheduled peptides may still be subject to import restrictions or therapeutic-goods classification depending on how they are marketed and supplied. Verify the current scheduling status directly at tga.gov.au before procurement.

Import Considerations

Pre-filled pens are treated similarly to vials under Australian Border Force and TGA import rules. Imports of research peptides may be subject to Australian Border Force inspection and TGA personal-importation or unapproved-therapeutic-goods requirements, depending on quantity, declared use, and any therapeutic claims attached to the consignment.

This section is descriptive, not legal advice. Procurement officers should consult the current TGA scheduling instrument and, where institutional risk warrants it, a regulatory affairs professional before placing an order.

Researchers building a broader regenerative-peptide procurement file may also review the Body Pharm BPC-157 & TB500 32 Pen and the Body Pharm CJC-1295 & Ipamorelin 20 Pen pages.

Frequently Asked Questions

Question	Short Answer
Concentration	50 mg GHK-Cu per pen
Dose count	~30 doses at ~3 mg per dose
Australian availability	Yes — available via JCSG.org
Human use status	Not approved for human therapeutic use